Researchers marked the significant progress of the diagnosis and treatment of non -Hodgkin lymphoma (NHL), and it has been verified Kobas® EZH2 mutation test is an EZH2 mutation with a diagnostic tool that aims to detect functional functions. This study was, INC. Peter Schlag and his colleagues, including Johnny Shyu, Sylwia Karwowska, Chitra Manohar, Chitra Manohar, Huan Truong and Guili ZHANG, and Carolinas Pathology, Dr. John Longshore. Plos ONE for the peer review.
The Cobas® EZH2 mutation test aims to identify the functional income mutations of the EZH2 gene. In the EZH2 gene, it is common in the large -diffused large B -cell lymphoma (DLBCL) and filter (FL) cases. These mutations are usually related to poor progress and prognosis. The test is with Epizyme, INC. Cooperative development, an IPSEN company and EISAI Co., LTD. To support the clinical trials of Tazemetostat, Tazemetostat is aimed at EZH2’s apparent genetic therapy.
Peter Schlag said, “Kobas® The EZH2 test proves that the abnormality of the next -generation sequencing (NGS) emphasizes its reliability and accuracy in detecting EZH2 mutations. “In the technical performance verification (TPV) and clinical verification studies, high consistency rates are observed, including hundreds of clinical samples.
The research of TPV involves more than 100 commercial purchases, and reports the total agreement between Kobas> 98.1 %® Wild types and mutant positive EZH2 tests and NGS. Similarly, clinical verification research analyzes hundreds of samples of Tazemetostat’s clinical trials, showing high positive positive and negative percentage. These results prove the effectiveness of the test in the clinical environment, which paved the way for the FDA approval of the FDA in June 2020 as a partner diagnosis of patients with follicle lymphoma aimed at EZH2 mutations.TM (TAZEMETOSTAT), followed by recognized therapeutic product labels.
The main findings of verification research include a single and rare dual EZH2 mutation in the detection of FL and DLBCL samples. Repeated research proves the robustness of testing under various test conditions, which reports the accurate result of the low percentage mutation sample, and its ineffective rate is very low.
Peter Schlag emphasized clinical significance and pointed out:® The EZH2 test provides a fast and accurate method that can identify patients who will benefit from Tazemetostat, thereby improving the personalized therapy strategy of FL patients. ”
The Peter Schlag team also emphasized the widespread impact of this diagnostic tool on precision medicine. By promoting the appraisal of EZH2 mutation, Cobas® The EZH2 test plays a vital role in NHL’s targeted therapy, which is consistent with the increasing emphasis on personalized medicine in oncology.
In short, Kobas® The EZH2 mutation test represents the significant improvement of the NHL diagnosis situation, providing reliable, effective and clinical verified tools to detect EZH2 mutations. This breakthrough not only supports the target therapy of FL, but also emphasizes the importance of incorporating advanced diagnosis into personalized cancer care.
Journal reference
ShU, JY, Schlag, PA, Karwowska, SM, Manohar, CF, Truong, HM, Longshore, JW and ZHANG, G. (2023). The performance of the clinical sample of COBAS EZH2 mutation test to non -Hodgkin lymphoma patients. PLOS. Doi: https: //doi.org/10.1371/journal.pone.0292251
Willow -leaf knife oncol. November 2020; 21 (11): 1433–1442. DOI:
